Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice

被引:41
作者
Ölschläger, V
Pleschka, S
Fischer, T
Rziha, HJ
Wurzer, W
Stitz, L
Rapp, UR
Ludwig, S
Planz, O
机构
[1] Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Tubingen, Germany
[2] Univ Giessen, Inst Med Virol, D-35390 Giessen, Germany
[3] Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany
[4] Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany
关键词
influenza A virus; lung tumor; C-Raf; MEK; ERK; in vivo; mouse;
D O I
10.1038/sj.onc.1207883
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alterations in signalling via the Raf/MEK/ERK pathway interfere with influenza A virus replication in cell culture. While virus yields are reduced in cells expressing dominant-negative Raf or ERK, virus propagation is enhanced upon expression of constitutively active Raf or MEK. To study the impact of active Raf on influenza virus propagation in vivo, we investigated transgenic mice expressing an activated mutant of c-Raf (Raf-BxB) in the main target tissue of influenza virus, the lung. Raf-BxB expression results in multicentric alveolar adenomas. Influenza virus A infection of Raf-BxB mice results in increased disease symptoms and higher mortality rates. The immune response against viral pathogens in transgenic animals did not differ from wild-type mice as determined by the use of a Pseudorabies virus (PRV) as a model for a viral infection not affecting the lung. No significant differences of influenza virus titers in the lung of Raf-BxB and wild-type mice were observed. However, immunohistology revealed increased numbers of influenza NP-positive cells in the alveolar linings of Raf-BxB mice, demonstrating the strong tropism of influenza virus for cells expressing active Raf. These findings disclose the possibility to use modified influenza virus for the therapy of tumors with an activated Ras/Raf signalling pathway.
引用
收藏
页码:6639 / 6646
页数:8
相关论文
共 29 条
[1]   Seroconversion after influenza vaccination in patients with lung cancer [J].
Anderson, H ;
Petrie, K ;
Berrisford, C ;
Charlett, A ;
Thatcher, N ;
Zambon, M .
BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) :219-220
[2]  
Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219
[3]  
Bergmann M, 2001, CANCER RES, V61, P8188
[4]  
BOS JL, 1989, CANCER RES, V49, P4682
[5]   Humoral immune response to influenza vaccination in patients from high risk groups [J].
Brydak, LB ;
Machala, M .
DRUGS, 2000, 60 (01) :35-53
[6]  
CARD JP, 1995, CRIT REV NEUROBIOL, V9, P137
[7]  
Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X
[8]   Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice [J].
Fischer, T ;
Planz, O ;
Stitz, L ;
Rziha, HJ .
JOURNAL OF VIROLOGY, 2003, 77 (17) :9312-9323
[9]  
HALL WJ, 1976, AM REV RESPIR DIS, V113, P141
[10]  
Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185